Invivyd completes enrollment in Phase 3 DECLARATION trial of VYD2311 for COVID prevention

Invivyd

Invivyd

IVVD

0.00
  • Invivyd completed enrollment in the upsized Phase 3 DECLARATION trial of VYD2311 to prevent symptomatic COVID-19.
  • Top-line results have not been presented; data remain on track for release in late Q3 2026.
  • The study is designed to show whether a single intramuscular dose reduces symptomatic COVID versus placebo, with protection expected to extend beyond three months.
  • A second arm is testing monthly dosing versus placebo to support an option for more frequent protection in at-risk people.
  • The trial added about 500 participants to strengthen the likelihood of a clear efficacy readout amid variable COVID infection rates.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010701PRIMZONEFULLFEED9729377) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.